MD3365373T2 - Molecule de legare care inhibă dezvoltarea cancerului - Google Patents
Molecule de legare care inhibă dezvoltarea canceruluiInfo
- Publication number
- MD3365373T2 MD3365373T2 MDE20180831T MDE20180831T MD3365373T2 MD 3365373 T2 MD3365373 T2 MD 3365373T2 MD E20180831 T MDE20180831 T MD E20180831T MD E20180831 T MDE20180831 T MD E20180831T MD 3365373 T2 MD3365373 T2 MD 3365373T2
- Authority
- MD
- Moldova
- Prior art keywords
- binding molecules
- cancer growth
- inhibit cancer
- membrane
- extracellular portion
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3046—Stomach, Intestines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyrane Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP15191343 | 2015-10-23 | ||
EP16168647 | 2016-05-06 | ||
PCT/NL2016/050726 WO2017069628A2 (en) | 2015-10-23 | 2016-10-21 | Binding molecules that inhibit cancer growth |
Publications (1)
Publication Number | Publication Date |
---|---|
MD3365373T2 true MD3365373T2 (ro) | 2021-08-31 |
Family
ID=57190021
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MDE20180831T MD3365373T2 (ro) | 2015-10-23 | 2016-10-21 | Molecule de legare care inhibă dezvoltarea cancerului |
Country Status (26)
Country | Link |
---|---|
US (1) | US11939394B2 (ro) |
EP (2) | EP3365373B1 (ro) |
JP (3) | JP7296728B2 (ro) |
KR (1) | KR20180100305A (ro) |
CN (2) | CN108602888B (ro) |
AU (2) | AU2016340764B2 (ro) |
BR (1) | BR112018008068A2 (ro) |
CA (1) | CA3002957A1 (ro) |
CY (1) | CY1124108T1 (ro) |
DK (1) | DK3365373T3 (ro) |
EA (1) | EA201890866A1 (ro) |
ES (1) | ES2865482T3 (ro) |
HK (1) | HK1253914A1 (ro) |
HR (1) | HRP20210483T1 (ro) |
HU (1) | HUE055222T2 (ro) |
LT (1) | LT3365373T (ro) |
MA (2) | MA45517B1 (ro) |
MD (1) | MD3365373T2 (ro) |
MX (2) | MX2018004988A (ro) |
NZ (1) | NZ742290A (ro) |
PL (1) | PL3365373T3 (ro) |
RS (1) | RS61800B1 (ro) |
SG (1) | SG11201803359VA (ro) |
SI (1) | SI3365373T1 (ro) |
WO (1) | WO2017069628A2 (ro) |
ZA (1) | ZA201802758B (ro) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015130172A1 (en) | 2014-02-28 | 2015-09-03 | Merus B.V. | Antibodies that bind egfr and erbb3 |
NZ724815A (en) * | 2014-04-04 | 2017-11-24 | Bionomics Inc | Humanized antibodies that bind lgr5 |
LT3365373T (lt) | 2015-10-23 | 2021-05-25 | Merus N.V. | Surišančios molekulės, kurios inhibuoja vėžio augimą |
WO2017161414A1 (en) | 2016-03-22 | 2017-09-28 | Bionomics Limited | Administration of an anti-lgr5 monoclonal antibody |
US11993645B2 (en) | 2017-01-11 | 2024-05-28 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions comprising R-Spondin (RSPO) surrogate molecules |
JP7305543B2 (ja) * | 2017-01-26 | 2023-07-10 | スロゼン オペレーティング, インコーポレイテッド | 組織特異的Wntシグナル増強分子およびその使用 |
KR20190140945A (ko) | 2017-03-31 | 2019-12-20 | 메뤼스 엔.페. | NRG1 융합 유전자를 가지는 세포를 치료하기 위한 ErbB-2 및 ErbB-3 결합 이중특이적 항체 |
CA3068932A1 (en) * | 2017-07-06 | 2019-01-10 | Merus N.V. | Bispecific anti pd1-anti tim3 antibodies |
EA202090005A1 (ru) * | 2017-07-06 | 2020-06-18 | Мерус Н.В. | Антитела, модулирующие биологическую активность, проявляемую клеткой |
CN111094351A (zh) | 2017-08-09 | 2020-05-01 | 美勒斯公司 | 结合EGFR和cMET的抗体 |
BR112020019795A2 (pt) * | 2018-03-30 | 2021-01-05 | Merus N.V. | Anticorpo multivalente |
CA3104868A1 (en) * | 2018-07-09 | 2020-01-16 | Surrozen, Inc. | Tissue-specific wnt signal enhancing molecules and uses thereof |
WO2020139950A1 (en) * | 2018-12-27 | 2020-07-02 | H. Lee Moffitt Cancer Center And Research Institute Inc. | Bispecific antibody for membrane clearance of target receptors |
KR20210110600A (ko) * | 2018-12-31 | 2021-09-08 | 메뤼스 엔.페. | 혼합 결합 도메인 |
EA202191242A1 (ru) | 2018-12-31 | 2021-11-25 | Мерус Н.В. | Усеченные поливалентные мультимеры |
CN114426578A (zh) * | 2019-02-14 | 2022-05-03 | 美勒斯公司 | 结合egfr、her2及her3的结合部分的组合 |
WO2020174370A2 (en) | 2019-02-26 | 2020-09-03 | Janssen Biotech, Inc. | Combination therapies and patient stratification with bispecific anti-egfr/c-met antibodies |
TW202102544A (zh) | 2019-04-04 | 2021-01-16 | 日商小野藥品工業股份有限公司 | 雙特異性抗體 |
US11879013B2 (en) | 2019-05-14 | 2024-01-23 | Janssen Biotech, Inc. | Combination therapies with bispecific anti-EGFR/c-Met antibodies and third generation EGFR tyrosine kinase inhibitors |
JP2022545457A (ja) | 2019-08-19 | 2022-10-27 | メルス ナムローゼ フェンノートシャップ | Lgr5及びegfrに結合する抗体とトポイソメラーゼi阻害剤との組合せを用いる癌の治療 |
EP4051715A4 (en) * | 2019-11-01 | 2023-11-15 | The Regents of the University of California | DEGRADATION OF SURFACE PROTEINS USING A BISPECIFIC BINDING AGENT |
CA3169792A1 (en) * | 2020-03-05 | 2021-09-10 | Umc Utrecht Holding B.V. | Membrane ubiquitin ligases to target protein degradation |
US20230184745A1 (en) * | 2020-03-05 | 2023-06-15 | Umc Utrecht Holding B.V. | Screening method for effective target - E3 ligase combinations |
CN115698067A (zh) | 2020-04-24 | 2023-02-03 | 美勒斯公司 | 使用结合lgr5及egfr的抗体的癌症治疗 |
CN113862326A (zh) * | 2020-09-08 | 2021-12-31 | 复旦大学 | KREMEN1和/或ASGR1作为药物靶点在治疗SARS-CoV-2感染中的应用 |
KR20230120125A (ko) | 2020-12-15 | 2023-08-16 | 메뤼스 엔.페. | Lgr5 및 egfr에 결합하는 항체를 사용하는 암의 치료 |
EP4262867A1 (en) | 2020-12-18 | 2023-10-25 | Merus N.V. | Antibody composition |
CN114853889B (zh) * | 2021-02-03 | 2024-03-01 | 中国科学院动物研究所 | 针对人gpr48的单克隆抗体及其应用 |
CN113307882B (zh) * | 2021-05-12 | 2022-12-20 | 东北大学 | 靶向治疗Rspo过度激活导致的结直肠癌的融合蛋白SZ1及其偶联纳米药物 |
CN118055949A (zh) | 2021-10-06 | 2024-05-17 | 美勒斯公司 | 使用至少结合egfr的抗体治疗免疫检查点抑制剂治疗的具高egfr表达的癌症 |
CN117567628A (zh) * | 2023-03-07 | 2024-02-20 | 四川尚锐生物医药有限公司 | 一种单克隆抗体或其抗原结合片段及其抗肿瘤的用途 |
Family Cites Families (106)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4801687A (en) | 1986-10-27 | 1989-01-31 | Bioprobe International, Inc. | Monoclonal antibody purification process using protein A |
NZ226694A (en) | 1987-10-28 | 1994-04-27 | Oncogen | Human immunoglobulin produced by recombinant dna techniques |
US5151504A (en) | 1989-11-17 | 1992-09-29 | E. R. Squibb & Sons, Inc. | Method for purification of monoclonal antibodies |
GB9022543D0 (en) | 1990-10-17 | 1990-11-28 | Wellcome Found | Antibody production |
WO1993002190A1 (en) | 1991-07-15 | 1993-02-04 | The Wellcome Foundation Limited | Production of antibodies |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
DE29706518U1 (de) | 1997-04-11 | 1997-05-22 | Missel Gmbh & Co E | Trägersystem für Bade-, Dusch- oder Whirlwannen |
US20020062010A1 (en) | 1997-05-02 | 2002-05-23 | Genentech, Inc. | Method for making multispecific antibodies having heteromultimeric and common components |
ATE299938T1 (de) | 1997-05-02 | 2005-08-15 | Genentech Inc | Ein verfahren zur herstellung multispezifischer antikörper die heteromultimere und gemeinsame komponenten besitzen |
IL145849A0 (en) | 1999-04-15 | 2002-07-25 | Crucell Holland Bv | Recombinant protein production in a human cell using sequences encoding adenovirus e1 protein |
DE29915950U1 (de) | 1999-09-10 | 1999-12-30 | Cmw Automation Gmbh | Vorrichtung zum Elektrolytbefüllen der Zellen eines Akkumulators |
US20070111201A1 (en) | 2001-04-30 | 2007-05-17 | Benjamin Doranz | Reverse transfection of cell arrays for structural and functional analyses of proteins |
DK1600510T3 (da) | 2001-07-04 | 2007-06-25 | Chromagenics Bv | DNA-sekvenser med antirepressoraktivitet |
US7332580B2 (en) | 2002-04-05 | 2008-02-19 | The Regents Of The University Of California | Bispecific single chain Fv antibody molecules and methods of use thereof |
EP1510943A4 (en) | 2002-05-31 | 2007-05-09 | Celestar Lexico Sciences Inc | INTERACTION PREDICTION DEVICE |
CA2965865C (en) | 2002-07-18 | 2021-10-19 | Merus N.V. | Recombinant production of mixtures of antibodies |
MXPA05006724A (es) | 2003-01-07 | 2005-09-08 | Symphogen As | Metodo para producir proteinas policlonales recombinantes. |
CA2526284C (en) | 2003-06-25 | 2014-11-18 | Crucell Holland B.V. | Binding molecules for the treatment of myeloid cell malignancies |
AU2005250499B2 (en) | 2004-06-03 | 2011-12-08 | Novimmune S.A. | Anti-CD3 antibodies and methods of use thereof |
MX2007002856A (es) | 2004-09-02 | 2007-09-25 | Genentech Inc | Metodos para el uso de ligandos receptores de muerte y anticuerpos c20. |
JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
US20090246206A1 (en) | 2005-02-23 | 2009-10-01 | Merrimack Pharmaceuticals, Inc. | Bispecific binding agents for modulating biological activity |
US20060212956A1 (en) | 2005-03-14 | 2006-09-21 | Genentech, Inc. | Animal model of ligand activated HER2 expressing tumors |
JP5620626B2 (ja) | 2005-03-31 | 2014-11-05 | 中外製薬株式会社 | 会合制御によるポリペプチド製造方法 |
JP5474531B2 (ja) | 2006-03-24 | 2014-04-16 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | 操作されたヘテロ二量体タンパク質ドメイン |
EP2035456A1 (en) | 2006-06-22 | 2009-03-18 | Novo Nordisk A/S | Production of bispecific antibodies |
PL2059533T3 (pl) | 2006-08-30 | 2013-04-30 | Genentech Inc | Przeciwciała wieloswoiste |
US8290739B2 (en) | 2006-10-20 | 2012-10-16 | Amfit, Inc. | Method for determining relative mobility of regions of an object |
AU2007353412A1 (en) | 2006-11-21 | 2008-11-20 | Fox Chase Cancer Center | Anti-EGFR family antibodies, bispecific anti-EGFR family antibodies and methods of use thereof |
MX2009008656A (es) | 2007-02-16 | 2009-11-10 | Merrimack Pharmaceuticals Inc | Anticuerpos contra erbb3 y usos de los mismos. |
WO2008119353A1 (en) | 2007-03-29 | 2008-10-09 | Genmab A/S | Bispecific antibodies and methods for production thereof |
WO2008119566A2 (en) | 2007-04-03 | 2008-10-09 | Micromet Ag | Cross-species-specific bispecific binders |
US7705103B2 (en) | 2007-06-22 | 2010-04-27 | 3M Innovative Properties Company | Polydiorganosiloxane polyoxamide copolymers |
PT2173379E (pt) | 2007-07-02 | 2015-11-24 | Oncomed Pharm Inc | Composições e métodos para o tratamento e diagnóstico de cancro |
WO2009051974A1 (en) | 2007-10-17 | 2009-04-23 | Nuvelo, Inc. | Antibodes to cll-1 |
EP2235536A4 (en) | 2007-12-20 | 2011-05-04 | Lab Corp America Holdings | HER-2 DIAGNOSTIC METHODS |
US9266967B2 (en) | 2007-12-21 | 2016-02-23 | Hoffmann-La Roche, Inc. | Bivalent, bispecific antibodies |
US20090162359A1 (en) | 2007-12-21 | 2009-06-25 | Christian Klein | Bivalent, bispecific antibodies |
US8242247B2 (en) | 2007-12-21 | 2012-08-14 | Hoffmann-La Roche Inc. | Bivalent, bispecific antibodies |
SI2235064T1 (sl) | 2008-01-07 | 2016-04-29 | Amgen Inc. | Metoda za izdelavo heterodimernih molekul - protitelesa fc z uporabo elektrostatičnih usmerjevalnih učinkov |
AU2009211148B2 (en) | 2008-02-05 | 2014-08-28 | Zymeworks Inc. | Methods for determining correlated residues in a protein or other biopolymer using molecular dynamics |
CN112481300A (zh) | 2008-06-27 | 2021-03-12 | 莫鲁斯股份有限公司 | 产生抗体的非人哺乳动物 |
JP5719298B2 (ja) | 2008-08-29 | 2015-05-13 | シムフォゲン・アクティーゼルスカブSymphogen A/S | 組換え抗上皮増殖因子受容体抗体組成物 |
BRPI0921586A2 (pt) | 2008-11-18 | 2019-09-24 | Merrimack Pharmaceuticals Inc | articuladores de albumina de soro humana e conjugados destes |
BRPI1007321A2 (pt) | 2009-01-15 | 2018-07-10 | Laboratory Corp America Holdings | métodos para medir e/ou quantificar a presença e/ou quantidade de her-3 ou her-3 em um complexo em uma amostra de um paciente, e para determinar se um indivíduo com um câncer é provável de responder ao tratamento com uma terapia alvejada, e, anticorpo. |
CN102365296A (zh) | 2009-01-26 | 2012-02-29 | 根马布股份公司 | 用于生成抗体混合物的方法 |
UA106070C2 (uk) | 2009-03-20 | 2014-07-25 | Дженентек, Інк. | Антитіло, що специфічно зв'язується з egfr і her3 |
US9067986B2 (en) | 2009-04-27 | 2015-06-30 | Oncomed Pharmaceuticals, Inc. | Method for making heteromultimeric molecules |
TWI507525B (zh) | 2009-06-26 | 2015-11-11 | Regeneron Pharma | 具天然免疫球蛋白形式之易分離的雙專一性抗體 |
US9345661B2 (en) | 2009-07-31 | 2016-05-24 | Genentech, Inc. | Subcutaneous anti-HER2 antibody formulations and uses thereof |
IN2012DN01518A (ro) | 2009-08-21 | 2015-06-05 | Merrimack Pharmaceuticals Inc | |
WO2011028952A1 (en) | 2009-09-02 | 2011-03-10 | Xencor, Inc. | Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens |
WO2011056124A1 (en) | 2009-11-04 | 2011-05-12 | Affibody Ab | Her3 binding polypeptides |
RS59001B1 (sr) | 2010-02-08 | 2019-08-30 | Regeneron Pharma | Miš sa zajedničkim lakim lancem |
US20130185821A1 (en) | 2010-02-08 | 2013-07-18 | Regeneron Pharmaceuticals, Inc. | Common Light Chain Mouse |
WO2011143545A1 (en) | 2010-05-14 | 2011-11-17 | Rinat Neuroscience Corporation | Heterodimeric proteins and methods for producing and purifying them |
DK2606064T3 (en) | 2010-08-16 | 2015-04-20 | Novimmune Sa | Methods for generating multispecific and multivalent antibodies |
PT2606070T (pt) | 2010-08-20 | 2017-03-31 | Novartis Ag | Anticorpos para o recetor 3 do fator de crescimento epidérmico (her3) |
TW201302793A (zh) | 2010-09-03 | 2013-01-16 | Glaxo Group Ltd | 新穎之抗原結合蛋白 |
US9155802B2 (en) | 2010-11-01 | 2015-10-13 | Symphogen A/S | Pan-HER antibody composition |
CN103429620B (zh) | 2010-11-05 | 2018-03-06 | 酵活有限公司 | 在Fc结构域中具有突变的稳定异源二聚的抗体设计 |
KR20140053865A (ko) | 2011-02-24 | 2014-05-08 | 메리맥 파마슈티컬즈, 인크. | 항-erbb3제를 포함하는 조합 요법 |
CN103429262A (zh) | 2011-03-15 | 2013-12-04 | 梅里麦克制药股份有限公司 | 克服对erbb途径抑制剂的抗性 |
KR102108521B1 (ko) | 2011-03-25 | 2020-05-11 | 아이크노스 사이언스 에스. 아. | 헤테로 이량체 면역글로불린 |
GB201106395D0 (en) * | 2011-04-14 | 2011-06-01 | Hubrecht Inst | Compounds |
EP2707391B1 (en) | 2011-05-13 | 2017-11-08 | Gamamabs Pharma | Antibodies against her3 |
KR20140033152A (ko) | 2011-06-20 | 2014-03-17 | 교와 핫꼬 기린 가부시키가이샤 | 항erbB3 항체 |
KR20140048276A (ko) * | 2011-07-15 | 2014-04-23 | 온코메드 파마슈티칼스, 인크. | Rspo 결합제 및 이의 용도 |
US9567827B2 (en) | 2013-07-15 | 2017-02-14 | Downhole Technology, Llc | Downhole tool and method of use |
CA2791109C (en) | 2011-09-26 | 2021-02-16 | Merus B.V. | Generation of binding molecules |
EP2760893B1 (en) | 2011-09-30 | 2018-09-12 | Regeneron Pharmaceuticals, Inc. | Anti-erbb3 antibodies and uses thereof |
WO2013078191A1 (en) | 2011-11-23 | 2013-05-30 | Medimmune, Llc | Binding molecules specific for her3 and uses thereof |
MX362521B (es) | 2011-12-05 | 2019-01-22 | Novartis Ag | Anticuerpos para el receptor del factor de crecimiento epidermico 3 (her3). |
UY34488A (es) | 2011-12-05 | 2013-07-31 | Novartis Ag | Anticuerpos dirigidos al receptor de factor de crecimiento epidérmico 3 (her3) dirigidos contra el dominio iii y dominio iv del her3 |
CN102448183A (zh) | 2012-01-18 | 2012-05-09 | 大唐移动通信设备有限公司 | 一种Uu接口重配置方法及设备 |
WO2013134686A1 (en) | 2012-03-09 | 2013-09-12 | Promega Corporation | pH SENSORS |
SG11201406079TA (en) | 2012-03-27 | 2014-10-30 | Genentech Inc | Diagnosis and treatments relating to her3 inhibitors |
AR090549A1 (es) * | 2012-03-30 | 2014-11-19 | Genentech Inc | Anticuerpos anti-lgr5 e inmunoconjugados |
MX360110B (es) | 2012-04-20 | 2018-10-23 | Merus Nv | Metodos y medios para la produccion de moleculas de tipo ig. |
TWI641619B (zh) | 2012-06-25 | 2018-11-21 | 美商再生元醫藥公司 | 抗-egfr抗體及其用途 |
CN110066338B (zh) | 2012-09-27 | 2024-04-09 | 美勒斯公司 | 作为T细胞衔接器的双特异性IgG抗体 |
CA2883264A1 (en) | 2012-10-15 | 2014-04-24 | Universitat Zurich Prorektorat Mnw | Bispecific her2 ligands for cancer therapy |
EA031184B1 (ru) | 2012-11-21 | 2018-11-30 | Янссен Байотек, Инк. | БИСПЕЦИФИЧЕСКИЕ К EGFR/c-Met АНТИТЕЛА |
JP2016510411A (ja) | 2013-02-04 | 2016-04-07 | オンコメッド ファーマシューティカルズ インコーポレイテッド | Wnt経路インヒビターによる処置の方法およびモニタリング |
US20160319034A1 (en) * | 2013-03-14 | 2016-11-03 | Oncomed Pharmaceuticals, Inc. | Met-binding agents and uses thereof |
EP2981828A1 (en) | 2013-04-05 | 2016-02-10 | Laboratory Corporation of America Holdings | Systems and methods for facilitating diagnosis, prognosis and treatment of cancer based on detection of her3 activation |
JP2016520586A (ja) | 2013-05-08 | 2016-07-14 | ザイムワークス,インコーポレイテッド | 二重特異性her2およびher3抗原結合性構築物 |
US9879081B2 (en) | 2013-06-25 | 2018-01-30 | Samsung Electronics Co., Ltd. | Protein complex, bispecific antibody including the protein complex, and method of preparation thereof |
US9551208B2 (en) | 2013-08-26 | 2017-01-24 | Halliburton Energy Services, Inc. | Identifying uncertainty associated with a stimulated reservoir volume (SRV) calculation |
WO2015066543A1 (en) | 2013-11-01 | 2015-05-07 | Board Of Regents, The University Of Texas System | Targeting her2 and her3 with bispecific antibodies in cancerous cells |
US11279770B2 (en) | 2014-02-28 | 2022-03-22 | Merus N.V. | Antibody that binds ErbB-2 and ErbB-3 |
WO2015130172A1 (en) * | 2014-02-28 | 2015-09-03 | Merus B.V. | Antibodies that bind egfr and erbb3 |
ME03525B (me) * | 2014-03-11 | 2020-04-20 | Regeneron Pharma | Anti-egfrviii antitijela i njihova primjena |
NZ724815A (en) | 2014-04-04 | 2017-11-24 | Bionomics Inc | Humanized antibodies that bind lgr5 |
MA41123A (fr) | 2014-12-02 | 2017-10-10 | Oncomed Pharm Inc | Polythérapie pour le traitement du cancer |
US10383945B2 (en) * | 2015-02-18 | 2019-08-20 | The United States of America as Represented by the Department of Verterans Affairs | Methods for DNA-dependent targeting of a cell permeant antibody |
ES2812303T3 (es) | 2015-07-10 | 2021-03-16 | Merus Nv | Anticuerpo que se une a CD3 humano |
LT3365373T (lt) | 2015-10-23 | 2021-05-25 | Merus N.V. | Surišančios molekulės, kurios inhibuoja vėžio augimą |
CN108367053A (zh) * | 2015-12-22 | 2018-08-03 | 诺华股份有限公司 | 使用生长分化因子15(gdf-15)治疗或改善代谢性疾病的方法 |
CN110997000A (zh) | 2017-03-31 | 2020-04-10 | 美勒斯公司 | 用于治疗ErbB-2/ErbB-3阳性肿瘤的抗体 |
KR20190140945A (ko) | 2017-03-31 | 2019-12-20 | 메뤼스 엔.페. | NRG1 융합 유전자를 가지는 세포를 치료하기 위한 ErbB-2 및 ErbB-3 결합 이중특이적 항체 |
WO2018212656A1 (en) | 2017-05-17 | 2018-11-22 | Merus N.V. | Combination of an erbb-2/erbb-3 bispecific antibody with endocrine therapy for breast cancer |
CN111094351A (zh) | 2017-08-09 | 2020-05-01 | 美勒斯公司 | 结合EGFR和cMET的抗体 |
MX2021007848A (es) * | 2018-12-27 | 2021-10-26 | Gigagen Inc | Proteinas de union a anti-ctla-4 y metodos de uso de las mismas. |
-
2016
- 2016-10-21 LT LTEP16794080.8T patent/LT3365373T/lt unknown
- 2016-10-21 WO PCT/NL2016/050726 patent/WO2017069628A2/en active Application Filing
- 2016-10-21 KR KR1020187014570A patent/KR20180100305A/ko not_active Application Discontinuation
- 2016-10-21 DK DK16794080.8T patent/DK3365373T3/da active
- 2016-10-21 MA MA45517A patent/MA45517B1/fr unknown
- 2016-10-21 AU AU2016340764A patent/AU2016340764B2/en active Active
- 2016-10-21 HU HUE16794080A patent/HUE055222T2/hu unknown
- 2016-10-21 CA CA3002957A patent/CA3002957A1/en active Pending
- 2016-10-21 EP EP16794080.8A patent/EP3365373B1/en active Active
- 2016-10-21 NZ NZ74229016A patent/NZ742290A/en unknown
- 2016-10-21 BR BR112018008068A patent/BR112018008068A2/pt active Search and Examination
- 2016-10-21 EA EA201890866A patent/EA201890866A1/ru unknown
- 2016-10-21 MX MX2018004988A patent/MX2018004988A/es unknown
- 2016-10-21 CN CN201680065283.5A patent/CN108602888B/zh active Active
- 2016-10-21 MD MDE20180831T patent/MD3365373T2/ro unknown
- 2016-10-21 PL PL16794080T patent/PL3365373T3/pl unknown
- 2016-10-21 SI SI201631138T patent/SI3365373T1/sl unknown
- 2016-10-21 RS RS20210479A patent/RS61800B1/sr unknown
- 2016-10-21 CN CN202211112405.5A patent/CN115925944A/zh active Pending
- 2016-10-21 MA MA054760A patent/MA54760A/fr unknown
- 2016-10-21 JP JP2018540363A patent/JP7296728B2/ja active Active
- 2016-10-21 SG SG11201803359VA patent/SG11201803359VA/en unknown
- 2016-10-21 EP EP21161572.9A patent/EP3912998A3/en active Pending
- 2016-10-21 ES ES16794080T patent/ES2865482T3/es active Active
- 2016-10-21 US US15/770,317 patent/US11939394B2/en active Active
-
2018
- 2018-04-23 MX MX2022000302A patent/MX2022000302A/es unknown
- 2018-04-25 ZA ZA2018/02758A patent/ZA201802758B/en unknown
- 2018-10-12 HK HK18113062.6A patent/HK1253914A1/zh unknown
-
2021
- 2021-03-24 HR HRP20210483TT patent/HRP20210483T1/hr unknown
- 2021-04-19 CY CY20211100338T patent/CY1124108T1/el unknown
- 2021-11-05 JP JP2021181173A patent/JP2023008754A/ja active Pending
-
2023
- 2023-08-31 AU AU2023222928A patent/AU2023222928A1/en active Pending
- 2023-11-29 JP JP2023201785A patent/JP2024023445A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MD3365373T2 (ro) | Molecule de legare care inhibă dezvoltarea cancerului | |
CY1122153T1 (el) | Μεθοδοι και μεσα για την παρασκευη ετεροδιμερων μοριων τυπου ig | |
CY1122278T1 (el) | Αντι il-36r αντισωματα | |
CY1123518T1 (el) | Ανθρωπινα αντισωματα enanti-tau | |
CY1122091T1 (el) | Μορια δεσμευσης-cd37 και ανοσοσυζευγματα εξ αυτων | |
CY1120471T1 (el) | Αντισωματα κατα του cd70 | |
CY1118014T1 (el) | Aνti-il-23 αντισωματα | |
CY1124028T1 (el) | Συνθεσεις και μεθοδοι για τα αντισωματα που στοχευουν την ερο | |
CY1122978T1 (el) | Αντισωματα εναντι-vla-4 | |
CY1117563T1 (el) | Αντισωματα κατα her3 και χρησεις αυτων | |
CY1117767T1 (el) | Rsv-ειδικα προσδενομενα μορια και μεσα για την παραγωγη αυτων | |
CR20140585A (es) | Proteinas de union a antigeno st2 | |
CY1121742T1 (el) | Αντισωματα s100a4 και θεραπευτικες χρησεις αυτων | |
EA201201435A1 (ru) | ГЕТЕРОДИМЕРНЫЕ АНТИТЕЛО-Fc-СОДЕРЖАЩИЕ БЕЛКИ И СПОСОБЫ ИХ ПОЛУЧЕНИЯ | |
CY1124849T1 (el) | Πρωτεϊνες ειδικης συνδεσης και χρησεις αυτων | |
EA200970909A1 (ru) | Новый антиген, ассоциированный с новообразованными сосудами опухолевых метастазов | |
CY1121466T1 (el) | Αντισωματα εναντι προσδεματων υποδοχεα β1 βραδυκινινης | |
EA201390472A1 (ru) | Новые молекулы, связывающиеся с egfr, и их иммуноконъюгаты | |
MX336682B (es) | Anticuerpos contra csf-1r humanos y usos de los mismos. | |
MX356337B (es) | Anticuerpos contra csf-1r humano y sus usos. | |
MA34091B1 (fr) | Anticorps anti-cd40 | |
MX2014014951A (es) | Agentes aglutinantes que modulan la trayectoria hippo y sus usos. | |
TR201903403T4 (tr) | İmmünoglobulin preparatı. | |
SG178886A1 (en) | Humanized anti-cdcp1 antibodies | |
BR112012007082A2 (pt) | anticorpos que se ligam especificamente ao receptor do fator de crescimento epidérmico |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
TC4A | Change of name of proprietor (patent for invention) |
Owner name: MERUS N.V., OLANDA; KONINKLIJKE NEDERLANDSE AKADEMIE VAN WETENSCHAPPEN, OLANDA; CROWN BIOSCIENCE NETHERLANDS B.V., OLANDA; FUNDACIO INSTITUT DE RECERCA BIOMEDICA (IRB BARCELONA), SPANIA; INSTITUTIO CATALANA DE RECERCA I ESTUDIS AVANCATS, SPANIA; Free format text: PREVIOUS NAME OF PROPRIETOR: MERUS N.V., OLANDA; KONINKLIJKE NEDERLANDSE AKADEMIE VAN WETENSCHAPPEN, OLANDA; OCELLO B.V., OLANDA; FUNDACIO INSTITUT DE RECERCA BIOMEDICA (IRB BARCELONA), SPANIA; INSTITUTIO CATALANA DE RECERCA I ESTUDIS AVANCATS, SPANIA; |
|
PD4A | Change of proprietorship (patent for invention) |
Owner name: MERUS N.V., NLYALELAAN 623584 CM UTRECHT, OLANDA;FUNDACIO INSTITUT DE RECERCA BIOMEDICA, ESBALDIRI REIXAC 1008028 BARCELONA, SPANIA;INSTITUCIO CATALANA DE RECERCA I ESTUDIS, ESPASSEIG LLUIS COMPANYS, 2308010 BARCELONA, SPANIA Free format text: PREVIOUS PROPRIETOR: MERUS N.V., NLYALELAAN 623584 CM UTRECHT, OLANDA;KONINKLIJKE NEDERLANDSE AKADEMIE VAN WETENSCHAPPEN, NLKLOVENIERSBURGWAL 291011 JV AMSTERDAM, OLANDA;CROWN BIOSCIENCE NETHERLANDS B.V., NLYALELAAN 423584 CM UTRECHT, OLANDA;FUNDACIO INSTITUT DE RECERCA BIOMEDICA, ESBALDIRI REIXAC 1008028 BARCELONA, SPANIA;INSTITUCIO CATALANA DE RECERCA I ESTUDIS, ESPASSEIG LLUIS COMPANYS, 2308010 BARCELONA, SPANIA |